- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- 4mg CLS-TA Suprachoriodal Injection, Sham Procedure
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced May 21, 2026, 6:55 PM EDT